Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11026931 Methods for the administration of certain VMAT2 inhibitors

Patent 11026931 was granted and assigned to Neurocrine Biosciences on June, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Neurocrine Biosciences

0

Current Assignee

Neurocrine Biosciences

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Grace S. Liang0

Christopher F. O'Brien0

Dao Tuyet Thai-Cuarto0

Date of Patent

June 8, 2021

0

Patent Application Number

169833340

Date Filed

August 3, 2020

0

Patent Citations

US Patent 10160757 Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)

US Patent 10065952 Valbenazine salts and polymorphs thereof

US Patent 10689380 Crystalline forms of valbenazine ditosylate

Patent Citations Received

US Patent 11439629 Methods for the administration of certain VMAT2 inhibitors

US Patent 11654142 Methods for the administration of certain VMAT2 inhibitors

0

US Patent 11311532 High dosage valbenazine formulation and compositions, methods, and kits related thereto

Patent Primary Examiner

0

Patent abstract

Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11026931 Methods for the administration of certain VMAT2 inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool

By using this site, you agree to our Terms of Service.